FBXO17 Inhibits the Wnt/β-Catenin Pathway and Proliferation of Ishikawa Cells.

Int J Med Sci

Insitute of Obstetrics and Gynecology, Hospital of Obstetrics and Gynecology, Fudan University, Shanghai 200082, People's Republic of China.

Published: August 2022

AI Article Synopsis

  • Uterine corpus endometrial carcinoma (UCEC) is a rapidly increasing cancer type in women, with the Wnt/β-catenin signaling pathway playing a key role in its development.
  • FBXO17, a member of the F-box family, is found to be significantly downregulated in UCEC tissues, linked to higher tumor grades and increased cell proliferation in the Ishikawa cell line.
  • The study suggests that FBXO17 may act as a novel inhibitor of endometrial tumor growth by regulating the Wnt signaling pathway and influencing the expression of adhesion molecules like E-cadherin and N-cadherin.

Article Abstract

Uterine corpus endometrial carcinoma (UCEC) is one of the most common types of cancer in women, and the incidence is rapidly increasing. Studies have shown that various signaling pathways serve crucial roles in the tumorigenesis of UCEC, amongst which the Wnt/β-catenin pathway is of great interest due to its crucial role in cell proliferation and the huge potential as a therapeutic target. In the present study, it was shown that FBXO17, which is a member of the F-box family, is abnormally downregulated in UCEC tissues compared with non-tumor endometrial tissues, and this was significantly associated with the clinical histological grade, as well as the abnormal proliferation of the UCEC cell line, Ishikawa, both and . Besides, the results suggested that FBXO17 may inhibit the Wnt/β-catenin signaling pathway and influence the expression of adhesion molecules, such as E-cadherin and N-cadherin in Ishikawa cells. In conclusion, these findings indicate that FBXO17 is a novel inhibitor of endometrial tumor development and it likely exerts effects via regulation of the Wnt signaling pathway.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413558PMC
http://dx.doi.org/10.7150/ijms.60335DOI Listing

Publication Analysis

Top Keywords

wnt/β-catenin pathway
8
ishikawa cells
8
signaling pathway
8
fbxo17
4
fbxo17 inhibits
4
inhibits wnt/β-catenin
4
pathway
4
pathway proliferation
4
proliferation ishikawa
4
cells uterine
4

Similar Publications

Osteoporosis, affecting the entire skeletal system, can cause bone mass to diminish, thereby reducing bone strength and elevating fracture risk. Fracture nonunion and bone defects are common in patients with fractures, and pain and loss of function may cause serious distress. The search for a new therapeutic strategy is essential because of the limited therapeutic options available.

View Article and Find Full Text PDF

Radiation therapy (RT) is fundamental to the fight against cancer because of its exceptional ability to target and destroy cancer cells. However, conventional radiation therapy can significantly affect the adjacent normal tissues, leading to fibrosis, inflammation, and decreased organ function. This tissue damage not only reduces the quality of life but also prevents the total elimination of cancer.

View Article and Find Full Text PDF

Purpose: R-spondin3 (RSPO3), a mammalian-specific amplifier of WNT signaling pathway, maintains the homeostasis of various adult stem cells. However, its expression at the limbus and the effect on limbal epithelial stem cells (LESCs) remains unclear. We investigated the impact of RSPO3 on the proliferation and self-renewal of LESCs and explored its molecular mechanisms.

View Article and Find Full Text PDF

Tumors require ample protein synthesis to grow, and aminoacyl-tRNA synthetases, as critical translation factors, are expected to support cancer progression. Unexpectedly, overexpression of seryl-tRNA synthetase (SerRS) suppresses primary tumor growth of breast cancer. However, the effects of SerRS on metastasis have not been studied.

View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) is infamous for its aggressive phenotype and poorer prognosis when compared to other breast cancer subtypes. One factor contributing to this poor prognosis is that TNBC lacks expression of the receptors that available hormonal or molecular-oriented therapies attack. New treatments that exploit biological targets specific to TNBC are desperately needed to improve patient outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!